Aduro Biotech, Inc. (Nasdaq:ADRO) announced that it has established European subsidiary headquarters at the BioNovion site in Oss, Netherlands now called Aduro Biotech Europe. On October 30, 2015, Aduro acquired BioNovion, a biopharmaceutical antibody discovery and development company, to broaden its technology portfolio and increase its immunotherapy capabilities.
| Website | http://www.aduro.com |
| Revenue | $63.4 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2011 |
| Phone | +31 6 53215691 |
| Industry | Pharmaceuticals, Antibody, Therapeutics, Oncology, Immunology |
| Web Rank | 2 Million |
| Keywords | Biotechnology, Biopharmaceutical, Life Sciences, Pharmaceutical, Biopharma, Antibody, Drug Development, Biologics, Immunotherapy, Immuno-Oncology, Therapeutics, Clinical Trials, Oncology, Cancer Treatment, Research, Development, Healthcare, Regulatory Affairs, Manufacturing |
Looking for a particular BioNovion employee's phone or email?
BioNovion Questions
The BioNovion annual revenue was $63.4 million in 2026.
BioNovion is based in Oss, North Brabant.
Related Companies
G2Crowd Trusted
300K+
Plugin Users
